William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors, primarily centered around Harrow Health’s strategic acquisition of Melt Pharmaceuticals. This acquisition provides Harrow with a promising new asset, MELT-300, which is poised for a potential launch in 2028. MELT-300, an innovative opioid- and IV-free sedation product, has shown superior results in clinical trials and is expected to fill a significant market need in various medical procedures.
Furthermore, Harrow’s plan to utilize its existing commercial infrastructure and ophthalmic customer base to support the launch of MELT-300 demonstrates a well-thought-out strategy for market penetration. The company’s pipeline also includes other promising assets like MELT-210 and MELT-400, which could further enhance its market position. These strategic moves and the potential for international market access form the basis of Brown’s optimistic outlook on Harrow Health’s stock.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $70.00 price target.